GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Biocartis Group NV (XBRU:BCART) » Definitions » EV-to-EBIT

Biocartis Group NV (XBRU:BCART) EV-to-EBIT : -2.97 (As of May. 28, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Biocartis Group NV EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Biocartis Group NV's Enterprise Value is €154.31 Mil. Biocartis Group NV's EBIT for the trailing twelve months (TTM) ended in Jun. 2023 was €-51.94 Mil. Therefore, Biocartis Group NV's EV-to-EBIT for today is -2.97.

The historical rank and industry rank for Biocartis Group NV's EV-to-EBIT or its related term are showing as below:

XBRU:BCART' s EV-to-EBIT Range Over the Past 10 Years
Min: -20.01   Med: -5.34   Max: -2.1
Current: -2.97

During the past 11 years, the highest EV-to-EBIT of Biocartis Group NV was -2.10. The lowest was -20.01. And the median was -5.34.

XBRU:BCART's EV-to-EBIT is not ranked
in the Medical Diagnostics & Research industry.
Industry Median: 21.44 vs XBRU:BCART: -2.97

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Biocartis Group NV's Enterprise Value for the quarter that ended in Jun. 2023 was €161.16 Mil. Biocartis Group NV's EBIT for the trailing twelve months (TTM) ended in Jun. 2023 was €-51.94 Mil. Biocartis Group NV's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2023 was -32.23%.


Biocartis Group NV EV-to-EBIT Historical Data

The historical data trend for Biocartis Group NV's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biocartis Group NV EV-to-EBIT Chart

Biocartis Group NV Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -10.31 -5.46 -5.58 -4.97 -2.69

Biocartis Group NV Semi-Annual Data
Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -4.97 - -2.69 -

Competitive Comparison of Biocartis Group NV's EV-to-EBIT

For the Diagnostics & Research subindustry, Biocartis Group NV's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biocartis Group NV's EV-to-EBIT Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Biocartis Group NV's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Biocartis Group NV's EV-to-EBIT falls into.



Biocartis Group NV EV-to-EBIT Calculation

Biocartis Group NV's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=154.305/-51.944
=-2.97

Biocartis Group NV's current Enterprise Value is €154.31 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Biocartis Group NV's EBIT for the trailing twelve months (TTM) ended in Jun. 2023 was €-51.94 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biocartis Group NV  (XBRU:BCART) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Biocartis Group NV's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Jun. 2023 ) =EBIT / Enterprise Value (Q: Jun. 2023 )
=-51.944/161.1604717
=-32.23 %

Biocartis Group NV's Enterprise Value for the quarter that ended in Jun. 2023 was €161.16 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Biocartis Group NV's EBIT for the trailing twelve months (TTM) ended in Jun. 2023 was €-51.94 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biocartis Group NV EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Biocartis Group NV's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Biocartis Group NV (XBRU:BCART) Business Description

Traded in Other Exchanges
N/A
Address
Generaal de Wittelaan 11 B, Mechelen, BEL, 2800
Biocartis Group NV is a commercial-stage molecular diagnostics company. It provides diagnostic solutions aimed at improving clinical practice for patients, clinicians, payers, and the industry. The firm has developed an MDx Idylla molecular diagnostic system for oncology and infectious disease segments. Its products include EGFR mutation assay, BRAF mutation test, NRAS mutation test, respiratory panel, etc. The firm derives the majority of its revenues from product sales.

Biocartis Group NV (XBRU:BCART) Headlines

No Headlines